RxDoctor Payments Data

Erin Castellano

Adult Health · Orangeburg, SCNPI 1407045404

Payments from drug & device makers

$2,418in general payments, 2019–2025

Across 124 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$231
  • Pfizer$207
  • Johnson & Johnson$202
  • AbbVie$202
  • Lilly USA, LLC$189
  • Novo Nordisk$150
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$2,31896%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,418 in reported general payments places this provider in the 70th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$17,828
Medicare patients
163
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$80,481
JardianceEmpagliflozin59$49,128
EntrestoSacubitril/Valsartan29$23,434
FarxigaDapagliflozin Propanediol21$20,067
XareltoRivaroxaban12$15,643
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,058
SymbicortBudesonide/Formoterol Fumarate29$8,039
Janumet XrSitagliptin Phos/Metformin Hcl11$6,056
Incruse ElliptaUmeclidinium Bromide12$4,256
Albuterol Sulfate HfaAlbuterol Sulfate53$1,444
Rosuvastatin Calcium156$1,374
Metoprolol Succinate97$1,247
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide40$1,002
Atorvastatin Calcium107$907
Valsartan46$903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$207$80,48194 claims
Boehringer IngelheimJardiance$149$49,12859 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$136$36,16463 claims
NovartisEntresto$84$23,43429 claims
Johnson & JohnsonXarelto$202$15,64312 claims
MerckJanumet Xr$85$6,05611 claims
GSKIncruse Ellipta$53$4,25612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 292 adult health providers in South Carolina.

Other adult health in Orangeburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →